Curve Biosciences is a technology company.
Curve Biosciences has raised $40.0M across 1 funding round.
Curve Biosciences has raised $40.0M in total across 1 funding round.
Curve Biosciences is a precision medicine biotech company developing Whole-Body Blood Tests powered by AI models trained on the Whole-Body Atlas, the world's largest manually curated collection of comprehensively characterized human tissue samples.[1][2][3][4] It serves doctors, patients with chronic diseases, insurers, and pharma companies by solving the problem of inaccurate, expensive, and late-stage monitoring through earlier, more accurate detection of disease states via simple blood tests anchored in tissue-level biological data.[1][3][4] The company has raised approximately $57.69M in total funding, including a $40M round in 2024 led by Luma Group to advance clinical validation, commercialization, and its new Dallas headquarters at Pegasus Park, with reported revenue between $1M-$10M and strong growth momentum from California origins to Texas expansion.[2][3]
Curve Biosciences was founded in 2021 by Ritish Patnaik (CEO, from Plano, Texas; Columbia undergrad, Stanford PhD), Chuba Oyolu, and Nathan Hunkapiller (PhD, ex-Stanford Wang Group alum named chief something in recent spotlight).[2][3][6] Patnaik launched the company several years ago from San Mateo, California, after pursuing advanced biotech research, driven by the need to create a molecular blueprint of the human body from tissue data to improve chronic disease monitoring beyond opaque blood-based models.[1][3][4] Early traction included a $17.69M venture round in May 2024 led by Life Extension Ventures and NZVC, followed by the pivotal $40M raise enabling HQ relocation to Dallas' Pegasus Park biotech hub, marking a return to Patnaik's Texas roots while retaining California operations.[2][3]
Curve rides the AI-driven precision medicine wave in biotech, targeting chronic disease monitoring—a market strained by ineffective tools amid aging populations and rising disease burdens.[1][3][5] Timing is ideal post-2024 funding boom, aligning with advances in multi-omics data and tissue-anchored AI, as investors bet on "next frontier" clinical testing with reimbursement paths.[3] Favorable forces include biotech hubs like Pegasus Park fostering innovation, demand for proactive diagnostics over reactive care, and convergence of health diagnostics, AI, and personalized treatments.[2][3] Curve influences the ecosystem by pioneering whole-body molecular mapping, potentially reshaping how pharma develops drugs and insurers manage costs through data-driven outcomes.[1][3]
Curve is poised to launch detailed platform info and chronic disease pipeline updates soon, accelerating commercialization of blood tests with $40M fueling clinical trials and Dallas scaling.[3] Trends like AI-tissue integration and value-based care will propel growth, evolving Curve from startup to ecosystem leader in transforming chronic disease management from reactive to predictive. As the first to blueprint the body at scale, it anchors biotech's shift to biological truth, promising alleviated patient pain and optimized medicine.[1][3]
Curve Biosciences has raised $40.0M in total across 1 funding round.
Curve Biosciences's investors include Luma Group.
Curve Biosciences has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2025 | $40.0M Series A | Luma Group |